Gilead shares drop after hours on plummeting Q4 hepatitis C drug sales – CNBC

Gilead shares drop after hours on plummeting Q4 hepatitis C drug sales – CNBC
CNBCGilead shares drop after hours on plummeting Q4 hepatitis C drug salesCNBCGilead Sciences on Tuesday said fourth-quarter sales of its flagship hepatitis C drugs fell by more than half amid increased competition and forecast a further slowdown next year, sending its shares lower after the closing bell. For full-year 2018, the …and more »
Gilead shares drop after hours on plummeting Q4 hepatitis C drug sales – CNBC